Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate governance disclosure regarding share allocations and does not contain financial performance data.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) on July 6, 2015. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction involved Dr K Slaoui (a connected person of Dr M Slaoui) and consisted of 5 ADSs at a price of $41.95 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Key Facts for Investor Verification
- Transaction Date: July 6, 2015 (Notified July 7, 2015).
- Connected Person: Dr K Slaoui (connected to Dr M Slaoui).
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan.
- Volume: 5 ADSs.
- Price: $41.95 per ADS.
- Reason: Revaluation of the cash element of the notional investment.